statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion...

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference May 14-15...

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines...

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in...

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 30, 2024, the Companys Board of Directors approved...

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for...

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arrowhead Pharmaceuticals Inc (ARWR), where a total of 9,321 contracts have traded so far...

Noteworthy Thursday Option Activity: ARWR, RBLX, MRNA

This is a Bearish indicator signaling ARWR's price could decline from here. Traders may explore shorting the stock or put options...

Arrowhead Pharmaceuticals (ARWR, $29.39) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 11, 2024

This indicator may be signaling that ARWR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Arrowhead Pharmaceuticals (ARWR, $29.39) entered Downtrend as Momentum indicator drops below 0 level on Mar 11, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

Arrowhead Pharmaceuticals (ARWR, $29.39) price exceeded its 50-day Moving Average on March 11, 2024

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Volume	630,837.00
52-Wk High	$41.36
52-Wk Low	$20.67

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.47	--	--	N/A
Q1'24	-$0.80	-$1.24	-55.58%	MISSED
Q4'23	-$0.61	-$1.02	-67.60%	MISSED
Q3'23	-$0.57	-$0.96	-68.63%	MISSED
Q2'23	-$0.62	$0.45	172.82%	BEAT

ARWR Arrowhead Pharmaceuticals Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals